RMC-6291 for Solid Cancers

Recruiting at 64 trial locations

Overseen By Revolution Medicines, Inc.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Revolution Medicines, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a new drug, RMC-6291, in adults with advanced cancers that have a specific mutation. The drug aims to block a faulty protein in these cancer cells to stop their growth.

Research Team

Revolution Medicines, Inc.

Principal Investigator

Revolution Medicines, Inc.

Eligibility Criteria

Adults over 18 with advanced solid tumors that have a specific mutation (KRASG12C) can join. They should have tried standard treatments, be in fairly good health, and able to do daily activities. Not for those who've had recent surgery or brain tumors/metastases.

Inclusion Criteria

I am 18 years old or older.

I have been treated with a KRASG12C inhibitor before.

My cancer has a specific KRASG12C mutation and cannot be removed by surgery.

Exclusion Criteria

I haven't had major surgery in the last 28 days or minor surgery in the last 7 days.

I have been treated with a KRASG12C inhibitor before.

I have a digestive issue that affects how my body absorbs medicine.

Treatment Details

Interventions

• RMC-6291 (KRAS G12C(ON) inhibitor)

Trial Overview The trial is testing RMC-6291, a new drug targeting the KRAS G12C mutation in cancer cells. It's given alone to find the safest high dose and best dose for Phase 2 trials based on how patients react and what levels of the drug appear in their blood.

Participant Groups

Group I: RMC-6291 Experimental Treatment 1 Intervention

Dose Escalation and Dose Expansion

Who Is Running the Clinical Trial?

Revolution Medicines, Inc.

Lead Sponsor

Trials

14

Recruited

4,500+